Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine (RIGVIR®) is currently rising 5.5 Million EUR (0.5 MEUR secured) to finance the commercialization process of next generation solution for unmet medical needs in oncology based on the existing product.
We have elaborated a registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the following:
It is expected that the company value would rise 3 times within the next two years but in 5 to 7 years period – 10 times, at least.
Clinical studies from 1968
First genetically non-modified virus
One of the fastest growing biotech companies of the Northern Europe
Proven in clinical practice for more than 10 years